BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37857528)

  • 21. Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.
    Denlinger CS; Keedy VL; Moyo V; MacBeath G; Shapiro GI
    Invest New Drugs; 2021 Dec; 39(6):1604-1612. PubMed ID: 34250553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.
    Liu D; Ma C; Lu P; Gong J; Ye D; Wang S; Peng P; Bai Y; Song Y; Chen J; Jiang O; Zhang G; Ba Y; Chen L; Pan J; Li Q; Zhang L; Gu S; Yin X; Cao B; Han W; Dong H; Guo J; Zhang H; Su H; Jiang Y; Ouyang W; Ma L; Sun Y; Zhang F; Lv J; Guo Y; Xu C; Qi J; Wang L; Wang X; Liu Z; Shen L
    Eur J Cancer; 2021 May; 148():1-13. PubMed ID: 33691262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.
    Patnaik A; Kang SP; Rasco D; Papadopoulos KP; Elassaiss-Schaap J; Beeram M; Drengler R; Chen C; Smith L; Espino G; Gergich K; Delgado L; Daud A; Lindia JA; Li XN; Pierce RH; Yearley JH; Wu D; Laterza O; Lehnert M; Iannone R; Tolcher AW
    Clin Cancer Res; 2015 Oct; 21(19):4286-93. PubMed ID: 25977344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
    Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
    Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
    Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
    Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
    Heinhuis KM; Carlino M; Joerger M; Di Nicola M; Meniawy T; Rottey S; Moreno V; Gazzah A; Delord JP; Paz-Ares L; Britschgi C; Schilder RJ; O'Byrne K; Curigliano G; Romano E; Patah P; Wang R; Liu Y; Bajaj G; Siu LL
    JAMA Oncol; 2020 Jan; 6(1):100-107. PubMed ID: 31697308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
    JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
    Guo Y; Zhang W; Ying J; Zhang Y; Pan Y; Qiu W; Fan Q; Xu Q; Ma Y; Wang G; Guo J; Su W; Fan S; Tan P; Wang Y; Luo Y; Zhou H; Li J
    Eur J Cancer; 2023 Mar; 181():26-37. PubMed ID: 36628898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
    Schöffski P; Tan DSW; Martín M; Ochoa-de-Olza M; Sarantopoulos J; Carvajal RD; Kyi C; Esaki T; Prawira A; Akerley W; De Braud F; Hui R; Zhang T; Soo RA; Maur M; Weickhardt A; Krauss J; Deschler-Baier B; Lau A; Samant TS; Longmire T; Chowdhury NR; Sabatos-Peyton CA; Patel N; Ramesh R; Hu T; Carion A; Gusenleitner D; Yerramilli-Rao P; Askoxylakis V; Kwak EL; Hong DS
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
    Wang Z; Zhao J; Ma Z; Cui J; Shu Y; Liu Z; Cheng Y; Leaw SJ; Wu Y; Ma Y; Tan W; Ma X; Zhang Y; Wang J
    Lung Cancer; 2020 Sep; 147():259-268. PubMed ID: 32769013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
    Zhang Q; Zhang J; Zhong H; Yuan Y; Yang L; Zhang Q; Ji D; Gong J; Li J; Yao Z; Qi C; Wang J; Lu L; Shi M; Qian X; Shen L; Li J; Hu X
    Cancer Immunol Immunother; 2023 Aug; 72(8):2729-2739. PubMed ID: 37115210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
    Friedlander M; Mileshkin L; Lombard J; Frentzas S; Gao B; Wilson M; Meniawy T; Baron-Hay S; Briscoe K; McCarthy N; Fountzilas C; Cervantes A; Ge R; Wu J; Spira A
    Br J Cancer; 2023 Sep; 129(5):797-810. PubMed ID: 37474720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.
    Becerra CR; Conkling P; Vogelzang N; Wu H; Hong S; Narwal R; Liang M; Tavakkoli F; Pandya N
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):917-25. PubMed ID: 25149088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
    Catenacci DVT; Kang YK; Park H; Uronis HE; Lee KW; Ng MCH; Enzinger PC; Park SH; Gold PJ; Lacy J; Hochster HS; Oh SC; Kim YH; Marrone KA; Kelly RJ; Juergens RA; Kim JG; Bendell JC; Alcindor T; Sym SJ; Song EK; Chee CE; Chao Y; Kim S; Lockhart AC; Knutson KL; Yen J; Franovic A; Nordstrom JL; Li D; Wigginton J; Davidson-Moncada JK; Rosales MK; Bang YJ;
    Lancet Oncol; 2020 Aug; 21(8):1066-1076. PubMed ID: 32653053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
    Salgia R; Patel P; Bothos J; Yu W; Eppler S; Hegde P; Bai S; Kaur S; Nijem I; Catenacci DV; Peterson A; Ratain MJ; Polite B; Mehnert JM; Moss RA
    Clin Cancer Res; 2014 Mar; 20(6):1666-75. PubMed ID: 24493831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.
    Strauss J; Deville JL; Sznol M; Ravaud A; Maruzzo M; Pachynski RK; Gourdin TS; Maio M; Dirix L; Schlom J; Donahue RN; Tsai YT; Wang X; Vugmeyster Y; Beier F; Seebeck J; Schroeder A; Chennoufi S; Gulley JL
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37236636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.
    Zhao Y; Ma Y; Zang A; Cheng Y; Zhang Y; Wang X; Chen Z; Qu S; He J; Chen C; Jin C; Zhu D; Li Q; Liu X; Su W; Ba Y; Hao Y; Chen J; Zhang G; Qu S; Li Y; Feng W; Yang M; Liu B; Ouyang W; Liang J; Yu Z; Kang X; Xue S; Yang G; Yan W; Yang Y; Liu Z; Peng Y; Fanslow B; Huang X; Zhang L; Zhao H
    J Hematol Oncol; 2023 May; 16(1):50. PubMed ID: 37158938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors.
    Keam B; Ock CY; Kim TM; Oh DY; Kang WK; Park YH; Lee J; Lee JH; Ahn YH; Kim HJ; Chang SK; Park J; Choi JY; Song YJ; Park YS
    Invest New Drugs; 2021 Dec; 39(6):1624-1632. PubMed ID: 34268711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.
    Papadopoulos KP; Kelley RK; Tolcher AW; Razak AR; Van Loon K; Patnaik A; Bedard PL; Alfaro AA; Beeram M; Adriaens L; Brownstein CM; Lowy I; Kostic A; Trail PA; Gao B; DiCioccio AT; Siu LL
    Clin Cancer Res; 2016 Mar; 22(6):1348-55. PubMed ID: 26490310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
    Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.